North Carolina is currently home to 2662 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma
NCT04301843
Recruiting
Difluoromethylornithine (DFMO) will be used in an open label, multicenter, study in combination with etoposide for subjects with relapsed/refractory neuroblastoma.
Gender:
ALL
Ages:
31 years and below
Trial Updated:
08/02/2024
Locations: Levine Children's Hospital, Charlotte, North Carolina
Conditions: Neuroblastoma
Register for Updates
OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages
NCT02523118
Recruiting
The purpose of this observational study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EoG, EoN and EoC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We are aiming to compare different tissue components such as inflammatory cell types with clinical symptoms. We want to see if scores on standard questionnaires can give us an i... Read More
Gender:
ALL
Ages:
3 years and above
Trial Updated:
08/02/2024
Locations: University of North Carolina, Chapel Hill, Chapel Hill, North Carolina
Conditions: Eosinophilic Gastrointestinal Disorders (EGIDs), Eosinophilic Esophagitis, Eosinophilic Colitis, Eosinophilic Gastritis, Eosinophilic Gastroenteritis
Register for Updates
Web-based Pain Coping Skills Training for Breast Cancer Survivors With AI-Associated Arthralgia
NCT05703178
Recruiting
The main goal of this clinical trial is to test benefits of completing online pain coping skills training program in women who have been diagnosed with stage I-III breast cancer, who have completed their primary cancer treatment, who are taking an AI medication, and who have arthralgia. Arthralgia is a type of joint, bone, and muscle pain that is a common side effect of AI medications. The main questions it aims to answer are: 1. Whether online pain coping skills training reduces the severity o... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2024
Locations: Duke University, Durham, North Carolina
Conditions: Breast Cancer, Arthralgia, Pain, Chronic
Register for Updates
Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252
NCT06126744
Recruiting
This is a Phase 1 open label study designed to assess the safety and tolerability of the oncolytic herpes simplex virus 1 (oHSV1) study drug, MVR-C5252, administered intratumorally by convection-enhanced delivery (CED) in patients with recurrent high-grade glioma. Once the safety and maximum tolerated dose (MTD) is established in the dose escalation portion of the trial, a dose expansion cohort at the recommended phase 2 dose (RP2D) in patients with isocitrate dehydrogenase (IDH) wildtype recurr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2024
Locations: Duke University, Durham, North Carolina
Conditions: Recurrent High Grade Glioma
Register for Updates
Examining the Effects of Vivo on Physical Function and Glycemic Level in Sedentary Older With Prediabetes.
NCT06458530
Recruiting
This is a 12-week randomized, controlled trial that seeks to examine the effect of Vivo on 1) change in lower extremity strength defined as number of chair stands done in 30 seconds and 2) change in average glycemic level (HbA1c) compared to a wait list control.
Gender:
ALL
Ages:
60 years and above
Trial Updated:
07/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: PreDiabetes, Older Adult, Muscle Loss, Muscle Weakness
Register for Updates
Dose Optimization of Caffeine for HIE
NCT06448780
Recruiting
This is a phase Ib, open-label, dose-validating and safety study of caffeine in neonates with hypoxic-ischemic encephalopathy (HIE) undergoing therapeutic hypothermia.
Gender:
ALL
Ages:
24 hours and below
Trial Updated:
07/26/2024
Locations: The University of North Carolina at Chapel Hill Newborn Critical Care Center, Chapel Hill, North Carolina
Conditions: Hypoxic-Ischemic Encephalopathy
Register for Updates
Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients
NCT06372964
Recruiting
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Gender:
ALL
Ages:
Between 10 years and 17 years
Trial Updated:
07/26/2024
Locations: Clinical Site, Kinston, North Carolina
Conditions: Bipolar Depression
Register for Updates
Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
NCT05546580
Recruiting
Iadademstat is being studied as a treatment for subjects with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML) with FMS-like tyrosine kinase mutation (FLT3 mut+). During the trial, iadademstat will be given in combination with gilteritinib, a drug that is already approved to treat patients with FLT3-mutated R/R AML.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/26/2024
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
Register for Updates
Optimization of a mHealth Physical Activity Promotion Intervention With Mindful Awareness for AYAO (OPT2MOVE)
NCT05375162
Recruiting
The purpose of the present study is to utilize Multiphase Optimization Strategy (MOST)1 to test four social support and mindfulness components (e-coaching, buddy, general mindfulness training, and MVPA-specific mindfulness training) in a 12-week mHealth moderate to vigorous intensity physical activity (MVPA) intervention in a sample of young adult cancer survivors (YACS), to improve quality of life (QOL) and decrease adverse effects and symptom burden. PRIMARY AIM To identify which components f... Read More
Gender:
ALL
Ages:
Between 18 years and 39 years
Trial Updated:
07/26/2024
Locations: Wake Forest School of Medicine, Winston-Salem, North Carolina
Conditions: Cancer
Register for Updates
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
NCT05975983
Recruiting
The goal of this clinical trial is to learn about INS018_055 in adults with Idiopathic Pulmonary Fibrosis (IPF). The primary objective is to evaluate the safety and tolerability of INS018_055 orally administered for up to 12 weeks in adult subjects with IPF compared to placebo.
Gender:
ALL
Ages:
40 years and above
Trial Updated:
07/25/2024
Locations: Southeastern Research Center, Winston-Salem, North Carolina
Conditions: Idiopathic Pulmonary Fibrosis (IPF)
Register for Updates
Inhaled Mannitol on Mucociliary Clearance in Moderate to Severe Cystic Fibrosis
NCT05740618
Recruiting
This study will provide important mechanistic information regarding the effect of inhaled mannitol (Bronchitol) in people with cystic fibrosis (PwCF) with moderate to severe disease who are already using elexacaftor/tezacaftor/ivacaftor (E/T/I). Many patients have already discontinued hypertonic saline and other pulmonary therapies because of the profound effect of E/T/I of their symptoms and lung function. Further, because both inhaled osmotic agents (i.e., Bronchitol, hypertonic saline \[HS\])... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/25/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Cystic Fibrosis
Register for Updates
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1
NCT05507203
Recruiting
This is a multicenter, randomized, placebo controlled study to evaluate the efficacy and safety of ABX464 given at 25 or 50 mg QD in inducing clinical remission in subjects with moderately to severely active ulcerative colitis who have inadequate response, no response, a loss of response, or an intolerance to either conventional therapies \[corticosteroids, immunosuppressant (i.e. azathioprine, 6-mercaptopurine, methotrexate)\] and/or advanced therapies \[biologics (TNF inhibitors, anti-integrin... Read More
Gender:
ALL
Ages:
16 years and above
Trial Updated:
07/25/2024
Locations: Charlotte Gastroenterology and Hepatology, P.L.L.C, Charlotte, North Carolina
Conditions: Ulcerative Colitis
Register for Updates